DOCUMENTS CONSIDERED BY RANDALL M. ZUSMAN, M.D.

DOC. NO.	DOCUMENT DESCRIPTION
1	U.S. Patent No. 7,932,268 (Rader)
2	U.S. Patent No. 8,618,135 (Rader)
3	Certified U.S. Patent No. 7,932,268 File History
4	U.S. Patent No. 8,618,135 File History
5	Certified U.S. Provisional Patent Application No. 60/550,915
6	"Bayer/PPD Implitapide Development Follows Zetia Model As Statin Add-On," <i>The Pink Sheet</i> , 66(7):17 (February 16, 2004)
7	Stein Presentation re Microsomal Triglygeride Transfer Protein (MTP) Inhibitor (implitapide) program (2004)
8	PPD Webpage Screenshot: PPD To Hold Analyst Day on February 5, 2004 (1/15/04)
9	Chandler et al., "CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans," <i>Journal of Lipid Research</i> , 44:1887-1901 (2003)
10	Chang et al., "Microsomal triglyceride transfer protein (MTP) inhibitors: Discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms," <i>Current Opinion in Drug Discovery & Development</i> , 5(4):562-570 (2002)
11	Shiomi & Ito, "MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion," <i>European Journal of Pharmacology</i> , 431:127-131 (2001)
12	Wetterau et al., "An MTP Inhibitor that Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits," <i>Science</i> , 282:751-754 (1998)



Petition for Inter Partes Review of USPN 7,932,268

DOC. NO.	DOCUMENT DESCRIPTION
13	Goldberg, "Clinical Trial Experience with Extended-Release Niacin (Niaspan): Dose-Escalation Study," <i>American Journal of Cardiology</i> , 82(12A):35U-38U (1998)
14	Davidson, "Combination Therapy for Dyslipidemia: Safety and Regulatory Considerations," <i>American Journal of Cardiology</i> , 90(10B):50K-60K (2002)
15	Goldberg et al., "Multiple-Dose Efficacy and Safety of an Extended-Release Form of Niacin in the Management of Hyperlipidemia," <i>American Journal of Cardiology</i> , 85:1100-1105 (2000)
16	Edwards & Moore, "Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomized, double blind trials," <i>BMC Family Practice</i> , 4:18 (2003)
17	Guay, "Update on Fenofibrate," <i>Cardiovascular Drug Reviews</i> , 20(4):281-302 (2002)
18	Physicians' Desk Reference (2003)
19	"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults(Adult Treatment Panel III) Final Report," <i>Circulation</i> , 106:3143-3421 (2002)
20	FDA Approves Zetia – first new class to treat cholesterol since statins introduced, (October 28, 2002), (available at http://www.drugs.com/news/fda-approves-zetia-first-new-class-cholesterol-since-statins-introduced-3164.html)
21	Physicians' Desk Reference (2004)



Petition for Inter Partes Review of USPN 7,932,268

DOC. NO.	DOCUMENT DESCRIPTION
22	Affidavit of Christopher Butler, Office Manager, Internet Archive, authenticating Internet Archive URLs (June 12, 2015) (attaching as Ex. A:
	PPD News Releases(2004/02/13) (available at https://web.archive.org/web/20040213233245/http://www.ppdi.com/PPD_U6.htm?ID=126662);
	PPD News & IR Presentations(2003/12/12) (available at https://web.archive.org/web/20031212193444/http://ppdi.com/PPD_6_12.htm);
	PPD News & IR Presentations (2004/06/04) (available at https://web.archive.org/web/20040604203252/http://www.ppdi.com/PPD_6_12.htm)).
23	Affidavit of Christopher Butler, Office Manager, Internet Archive, authenticating Internet Archive URLs (June 16, 2015) (attaching as Ex. A:
	PPD News & IR Presentations (2004/04/15) (available at https://web.archive.org/web/20040415065142/http://ppdi.com/PPD_6_12.htm)).
24	Margaret A. McDowell et al., "Anthropometric Reference Data for Children and Adults: U.S. Population, 1999-2002," <i>CDC Advance Data from Vital & Health Stats.</i> , 361 (2005).

